一种用于区分伯基特淋巴瘤与 CD10+弥漫性大 B 细胞淋巴瘤的新型流式细胞术抗体组合。

A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.

机构信息

Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Am J Clin Pathol. 2010 May;133(5):718-26. doi: 10.1309/AJCP0XQDGKFR0HTW.

PMID:20395518

Abstract

Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.

摘要

快速准确地区分伯基特淋巴瘤 (BL) 和 CD10+弥漫性大 B 细胞淋巴瘤 (DLBCL) 至关重要，因为它们的治疗方法不同。最近的研究已经描述了这两种淋巴瘤中几种不同表达的抗原。我们的目标是通过流式细胞免疫表型 (FCI) 确定这些标记物的使用是否有助于 BL 与 CD10+DLBCL 的鉴别诊断。确定了 23 例有可用冷冻保存样本的 CD10+B 细胞淋巴瘤（13 例 BL 和 10 例 CD10+DLBCL）。使用以下抗体进行多参数 FCI：CD18、CD20、CD43、CD44 和 CD54 以及同型对照。与 CD10+DLBCL 相比，BL 中 CD44 和 CD54 的表达明显较低（P=.001 和 P=.01）。CD18 和 CD43 的表达没有显著差异。我们的数据表明，BL 和 CD10+DLBCL 之间 CD44 和 CD54 的表达存在显著差异。